Client News

AFYREN announces the resumption of production at its plant after the successful technical shutdown

REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Rentschler Biopharma appoints Dr. Torsten Woehr as Chief Executive Officer

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Mallia Innovations Secures €3 Million Financing to Accelerate Commercial Expansion of the 8T3 Essentials Line

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax Announces Launch of Public Offering of American Depositary Shares

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos